Fuzeon enfuvirtide: Phase III; under review in the U.S. and EU

Combined results from the controlled, international Phase III TORO1 and 2 trials showed that 32.7% of patients who received Fuzeon plus an individualized regimen of anti-HIV drugs achieved undetectabl...